https://hcdp-mcr.co.uk/mrd-monitoring-in-aml-minimum-reporting-standards/2025-08-21T14:24:45+00:00https://hcdp-mcr.co.uk/aml/pmlrara/2026-02-01T11:05:43+00:00https://hcdp-mcr.co.uk/aml/npm1/2026-02-01T11:05:15+00:00https://hcdp-mcr.co.uk/aml/cbfb-myh11-and-runx1-runx1t1-core-binding-factor-cbf/2026-02-01T10:54:37+00:00https://hcdp-mcr.co.uk/aml/kmt2a-rearrangements/2026-02-01T11:03:06+00:00https://hcdp-mcr.co.uk/aml/deknup214/2026-02-01T10:57:54+00:00https://hcdp-mcr.co.uk/aml/bcrabl/2026-02-01T10:52:18+00:00https://hcdp-mcr.co.uk/post-transplant-mrd-monitoring/2025-08-21T14:27:25+00:00https://hcdp-mcr.co.uk/aml/mrd-assessment-for-patients-on-lower-intensity-regimens-e-g-venetoclax-and-azacitidine/2026-02-01T11:04:01+00:00https://hcdp-mcr.co.uk/citations-and-references/2025-07-31T09:59:05+00:00https://hcdp-mcr.co.uk/2025-10-24T14:33:55+00:00https://hcdp-mcr.co.uk/aml/2026-02-01T11:23:16+00:00https://hcdp-mcr.co.uk/all-mrd-overview/2026-03-03T12:24:26+00:00https://hcdp-mcr.co.uk/all-diagnostics-fact-sheet/2025-08-21T14:13:06+00:00https://hcdp-mcr.co.uk/b-all-mll-gene-rearrangement/2025-08-21T14:24:03+00:00https://hcdp-mcr.co.uk/b-all-bcrabl-positive/2025-08-21T14:23:32+00:00https://hcdp-mcr.co.uk/b-all-bcrabl-negative/2025-08-21T14:22:39+00:00https://hcdp-mcr.co.uk/bcrabl-negative-no-fusion-gene-mll-and-no-igvh-rearrangements/2025-08-21T14:23:04+00:00https://hcdp-mcr.co.uk/t-all-tcr-rearranged/2025-08-21T14:27:55+00:00https://hcdp-mcr.co.uk/t-all-tcr-rearranged-2/2025-08-21T14:28:24+00:00https://hcdp-mcr.co.uk/useful-diagnostic-prognostic-calculators/2026-02-20T18:13:01+00:00https://hcdp-mcr.co.uk/hods-pathways/2025-10-24T15:13:08+00:00https://hcdp-mcr.co.uk/hods-pathways/csf-analysis/2025-11-01T18:04:18+00:00https://hcdp-mcr.co.uk/hods-pathways/suspected-acute-leukaemia/2025-10-24T14:38:06+00:00https://hcdp-mcr.co.uk/hods-pathways/acute-myeloid-leukaemia-or-ambiguous-lineage-follow-up-options/2025-11-01T17:33:48+00:00https://hcdp-mcr.co.uk/hods-pathways/acute-lymphoblastic-leukaemia-follow-up-options/2025-10-24T09:24:05+00:00https://hcdp-mcr.co.uk/hods-pathways/cml-new-diagnosis/2025-10-24T09:33:05+00:00https://hcdp-mcr.co.uk/hods-pathways/mds-or-cmml-new-or-follow-up/2025-11-01T17:40:46+00:00https://hcdp-mcr.co.uk/hods-pathways/myeloproliferative-neoplasms-mpn/2025-10-24T10:08:59+00:00https://hcdp-mcr.co.uk/hods-pathways/aplastic-anaemia/2025-11-01T17:41:26+00:00https://hcdp-mcr.co.uk/hods-pathways/eosinophilia/2025-10-29T09:04:18+00:00https://hcdp-mcr.co.uk/hods-pathways/mast-cell-disorders/2025-11-01T17:42:52+00:00https://hcdp-mcr.co.uk/hods-pathways/lymphoproliferative-disorders-lpd/2025-11-01T17:47:20+00:00https://hcdp-mcr.co.uk/hods-pathways/cutaneous-t-cell-lymphoma/2025-10-24T10:54:44+00:00https://hcdp-mcr.co.uk/hods-pathways/plasma-cell-dyscrasia-and-amyloid/2025-12-21T15:26:10+00:00https://hcdp-mcr.co.uk/hods-pathways/cytopenias-unknown-cause/2025-10-24T14:10:29+00:00https://hcdp-mcr.co.uk/hods-pathways/cml-new/2025-11-01T17:37:06+00:00https://hcdp-mcr.co.uk/hods-pathways/morphology-review/2025-10-24T11:24:26+00:00https://hcdp-mcr.co.uk/hods-pathways/body-fluid-assessment/2025-11-01T18:00:34+00:00https://hcdp-mcr.co.uk/hods-pathways/whole-genome-sequencing/2025-10-24T13:41:31+00:00https://hcdp-mcr.co.uk/pathway-tool/2025-11-01T19:22:48+00:00https://hcdp-mcr.co.uk/aml/flt3-itd/2026-02-01T11:01:50+00:00https://hcdp-mcr.co.uk/transfusion-consent-faq/2026-01-07T15:28:17+00:00https://hcdp-mcr.co.uk/aml/cebpa-bizip-in-frame/2026-02-01T10:31:17+00:00https://hcdp-mcr.co.uk/aml/npm1-mut-flt3-itd/2026-02-01T10:40:26+00:00https://hcdp-mcr.co.uk/aml/no-molecular-mrd-marker/2026-02-01T10:49:48+00:00